Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

9.36
+1.0712.91%
Pre-market: 9.410.0500+0.53%06:07 EDT
Volume:12.04M
Turnover:110.40M
Market Cap:544.18M
PE:-3.80
High:9.88
Open:8.29
Low:8.05
Close:8.29
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:45.54M
Volume Ratio:0.96
T/O Rate:26.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:2.21
PE(LYR):-4.14

Loading ...

Capricor CFO Anthony Bergmann disposes of 25,000 shares worth $792,540

Reuters
·
May 05

Capricor EVP, General Counsel Karen Krasney disposes 25,000 shares for $792,548‬

Reuters
·
May 05

Capricor Therapeutics schedules first-quarter 2026 financial results conference call and webcast

Reuters
·
May 05

Press Release: Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

Dow Jones
·
May 05

Capricor Therapeutics (CAPR) Is Down 12.4% After New HOPE-3 Deramiocel Phase 3 Data Release - What's Changed

Simply Wall St.
·
May 03

Capricor reports Phase 3 HOPE-3 trial results for Deramiocel in Duchenne muscular dystrophy

Reuters
·
Apr 22

Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting

GlobeNewswire
·
Apr 22

Capricor Therapeutics (CAPR) Gets a Buy from Roth MKM

TIPRANKS
·
Apr 15

Capricor director Karimah Es Sabar disposes of $0.2 million common shares

Reuters
·
Apr 04

Capricor director Karimah Es Sabar disposes of common shares worth $3.5 million

Reuters
·
Apr 02

Capricor EVP, General Counsel Karen Krasney disposes of CAPR shares worth $0.8 million

Reuters
·
Apr 02

Capricor CFO Anthony Bergmann disposes of $0.8 million in common shares

Reuters
·
Apr 02

Capricor Therapeutics announces annual shareholder meeting, issues proxy statement

Reuters
·
Apr 01

Roth MKM Keeps Their Buy Rating on Capricor Therapeutics (CAPR)

TIPRANKS
·
Mar 20

Capricor Therapeutics Nears Key Milestones After Earnings Call

TIPRANKS
·
Mar 14

Capricor selloff today a buying opportunity, says Roth Capital

TIPRANKS
·
Mar 14

Alliance Global Partners Keeps Their Buy Rating on Capricor Therapeutics (CAPR)

TIPRANKS
·
Mar 14

Capricor Therapeutics Inc : B. Riley Raises Target Price to $63 From $50

THOMSON REUTERS
·
Mar 13

B. Riley Adjusts Price Target on Capricor Therapeutics to $63 From $50, Maintains Buy Rating

MT Newswires Live
·
Mar 13

Capricor Therapeutics Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 13